SCHEMBL6893490

SCHEMBL6893490

Nc1c(Cl)c(N2CCC3(C2)NC(=O)NC3=O)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 8/20 0.42
DDB1 Q16531 6/20 0.42
CCNC P24863 4/20 0.40
CDK8 P49336 4/20 0.40
CDK19 Q9BWU1 3/20 0.40
BRD4 O60885 2/20 0.35
CREBBP Q92793 2/20 0.35
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OGFRL1 Q5TC84 1/20 0.33
PIK3CA P42336 1/20 0.33
SCN9A Q15858 3/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
CSF1R P07333 1/20 0.33
FLT3 P36888 1/20 0.33
LRRK2 Q5S007 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894944 0.95 CDK8 (0.42) CRBNDDB1CCNCCDK8CDK19
SCHEMBL6894950 0.91 CRBN (0.42) CRBNDDB1CCNCCDK8CDK19
SCHEMBL6894488 0.85 CRBN (0.44) CRBNDDB1CCNCCDK8CDK19
SCHEMBL6891856 0.84 BRD4 (0.36) CRBNDDB1BRD4CREBBPPIK3CA
SCHEMBL6894450 0.82 CRBN (0.42) CRBNDDB1CCNCCDK8CDK19
SCHEMBL6893297 0.81 CRBN (0.39) CRBNDDB1CCNCCDK8CDK19
SCHEMBL584020 0.80 CHRNB2 (0.43)
SCHEMBL7874628 0.80 KDM4E (0.37) CRBNDDB1BRD4CREBBPPIK3CA
SCHEMBL6893682 0.80 CHEK1 (0.37) CRBNDDB1CCNCCDK8CDK19
SCHEMBL6891825 0.77 BRD4 (0.37) BRD4CREBBPPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CRBN 1562/4885DDB1 615/4885CCNC 2243/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CRBN 2219/4885DDB1 956/4885CCNC 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.